
Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Topas raises €22m in Series B financining
Topas Therapeutics GmbH has closed a €22m (~$26mn) Series B financing round co-led by Vesalius BioCapital III and BioMedPartners with participation...

Vifor Pharma inks $340m deal with Angion Biomedica Inc.
Under the deal, Zurich-based Vifor Pharma will pay $30m upfront, make a $30m equity investment in Angion Biomedica and hold out the prospect of...

Biotech companies launch Biotech Austria
According to Apeiron CEO and Biotech Austria founding president Peter LLewellyn-Davies, Austria's vibrant biotech sector needs a voice that can be...

Janssen presents one-shot COVID-19 vaccine data
Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

UK approves Biontech/Pfizer Covid-19 vaccine
Biontech SE in Mainz, Germany, and Pfizer Inc. announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) of the United Kingdom...